IMRX · 2 developments mapped · last assessed 2026-08-27
Market Ontology has mapped 2 macro, policy, and market developments to ImmunoGen, Inc. since 2026-08-27. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Last close
Unavailable
No published quote
Market cap
Unavailable
Equity value
Diluted shares
Unavailable
Latest reported
Sector
Unavailable
Listing
Unavailable
Filings
Unavailable
No published filing
Valuation
No validated run has been published for IMRX yet, so no modelled value is shown. The IMRX valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run IMRX on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
A validated filed-statement snapshot has not been published for IMRX. Missing data is not estimated or replaced with scenario assumptions.
Current case
Open question
FDA Approves Revolution Medicines' RASONQUE as First Broad RAS Inhibitor
Indirect competitive pressure or potential partnership opportunities in the broader oncology/targeted therapy space, depending on pipeline overlap or strategic shifts.
· Moves competitive landscape for pipeline assets, market share assumptions for existing or future products
What changed, by assumption
Competitive landscape for pipeline assets
2026-08-27FDA Approves Revolution Medicines' RASONQUE as First Broad RAS Inhibitor
Assumption not yet resolved
2026-08-27FDA Approves Revolution Medicines RASONQUE for Metastatic Pancreatic Adenocarcinoma